Most common Caplyta side effects, like sleepiness and nausea, are temporary and typically resolve within a few days to a few weeks as your body adjusts to the medication. The drug reaches steady state in about 5 days, with a half-life of roughly 18 hours, so your body is finding its new baseline relatively quickly. How long specific side effects linger depends on which ones you’re experiencing.
The Most Common Side Effects and How Often They Occur
Sleepiness is by far the most frequently reported side effect. In clinical trials for schizophrenia, 24% of people taking Caplyta experienced drowsiness or sedation, compared to 10% on placebo. For bipolar depression, the rate was lower at 13% versus 3% on placebo.
Nausea affected about 8 to 9% of people across trials, roughly double the placebo rate. Dry mouth showed up in about 5 to 6% of patients, compared to 1 to 2% on placebo. These three side effects account for the bulk of what people notice when they start Caplyta.
When Early Side Effects Typically Fade
The drowsiness, nausea, and dry mouth that show up in the first days of treatment generally fall into the “adjustment period” category. Your body needs about 5 days to reach a stable drug level in the bloodstream, and the initial side effects often feel strongest during this ramp-up phase. Most people find these effects ease within a few days to a few weeks.
Sleepiness tends to be the most persistent of the three, partly because Caplyta has strong activity at serotonin receptors that influence wakefulness. Taking the medication in the evening can help you sleep through the peak drowsiness rather than fighting it during the day. Nausea and dry mouth, for most people, fade faster as the body acclimates.
If any of these effects remain bothersome after several weeks or get worse over time rather than better, that’s worth raising with your prescriber. It may signal a need for dose adjustment or a different approach.
Why Caplyta Has a Lighter Side Effect Profile
One reason people search for Caplyta side effect timelines is that they’ve experienced heavier side effects on other antipsychotics and want to know what to expect. Caplyta works differently from many older medications in this class. Its binding affinity for serotonin receptors is about 60 times stronger than its affinity for dopamine receptors, and it only needs to occupy about 40% of dopamine receptors to be effective. Most antipsychotics require much higher dopamine receptor occupancy.
This matters because high dopamine blockade is what causes the stiffness, tremors, and involuntary movements that make many antipsychotics difficult to tolerate. Caplyta’s lower dopamine occupancy, combined with its dual action at dopamine receptors (partially activating some while blocking others), translates to a noticeably lower rate of these movement-related side effects.
Weight and Metabolic Changes Over Time
Weight gain is a major concern with many antipsychotics, and this is where Caplyta’s long-term data stands out. In short-term trials of 4 to 6 weeks, patients on Caplyta gained an average of 3.5 pounds versus 2.9 pounds on placebo, a negligible difference. In a one-year open-label study, patients actually lost weight on average: about 4 pounds at 6 months and 7 pounds at the one-year mark.
Cholesterol and blood sugar levels tell a similar story. Over 10 months of treatment, total cholesterol dropped an average of nearly 10 points, LDL cholesterol dropped about 8 points, and triglycerides decreased slightly. Blood sugar rose by only 3 points on average. Among patients who started with normal metabolic values, about 91% maintained normal blood sugar and 92% maintained normal triglycerides through the study period. These numbers are reassuring if you’re worried about the metabolic problems that often accompany long-term antipsychotic use.
Movement Side Effects and Tardive Dyskinesia
Tardive dyskinesia, the involuntary facial or body movements that can develop with antipsychotic use, is a concern with any medication in this class. Caplyta carries a warning for tardive dyskinesia because the long-term incidence hasn’t been fully established. No head-to-head trials have compared its tardive dyskinesia risk directly against other antipsychotics.
What is known is that the underlying pharmacology suggests lower risk. The reduced dopamine receptor occupancy and the serotonin-dopamine receptor balance both point toward fewer movement problems. But tardive dyskinesia can emerge after months or years of treatment, even at low doses, and it doesn’t always resolve when the medication is stopped. It may partially or completely remit after discontinuation, but there’s no guarantee. This is a side effect where duration is unpredictable and prevention through monitoring matters more than waiting it out.
How Other Medications Affect Duration
If you take other medications that slow down your liver’s ability to process Caplyta, the drug stays in your system at higher concentrations for longer. This can intensify and extend side effects. Certain antifungal medications, some antibiotics, and heart medications like diltiazem fall into this category.
Strong inhibitors of the liver enzyme that breaks down Caplyta can nearly quadruple the drug’s concentration in your blood. Moderate inhibitors roughly double it. In these situations, prescribers typically reduce the Caplyta dose significantly (to one-quarter or one-half the standard dose) to compensate. If you’ve started a new medication and your Caplyta side effects suddenly return or worsen, the interaction could be the reason. Your prescriber can check whether a dose adjustment is needed.
What to Expect in the First Month
The most realistic timeline looks something like this: expect the first week to be the roughest, particularly for drowsiness. By week two, most people notice the sleepiness becoming more manageable. Nausea and dry mouth, if they appear at all, often improve within the first week or two. By the end of the first month, the majority of people who are going to tolerate Caplyta well have settled into it.
Side effects that haven’t improved by 4 to 6 weeks are less likely to resolve on their own. That doesn’t necessarily mean you need to switch medications, but it’s a reasonable checkpoint to reassess with your prescriber whether the benefits are outweighing the downsides. For metabolic effects like weight and cholesterol, the data suggests Caplyta is one of the more neutral options in its class over the long term, so those are less likely to become a growing problem over months of use.